About Endovascular Engineering
Endovascular Engineering is a Healthcare company based in Menlo Park (United States) founded in 2019. It operates as an engineering services are provided to medical device manufacturers. Endovascular Engineering has raised $122 million across 4 funding rounds from investors including HHS, Cordis and 415 Capital. Its Indian entity Ing Vysya Bank Limited reported revenue of ₹2,262 Cr. Endovascular Engineering offers products and services including Hēlo Thrombectomy System. Its focus areas include Life Sciences, Hematology, Medical Devices and Surgical. Its competitors include Inari Medical, Akura Medical, Magneto Thrombectomy, EmerStat and Retriever Medical and 1 more; 3 of its 6 listed competitors have raised funding.
Company details
Endovascular Engineering was established in 2019 in Menlo Park, United States. Services in engineering are offered to companies involved in medical device manufacturing. Focus is placed on supporting product development and production processes within the medical technology sector. Operations are conducted from the United States, with resources accessible via the domain endovascularengineering.com. Expertise is directed toward endovascular applications in device engineering.
- Headquarters Menlo Park, United States
- SectorsHealthcare
- Website endovascularengineering.com
- Social LinkedIn
- Legal Name Ing Vysya Bank Limited
- Date of Incorporation 29 Mar, 1930
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹2,262 Cr
FY 2024 · 0% YoY
- Total Equity Funding$122M (USD)
in 4 rounds
- Latest Funding Round$80M (USD), Series C
Apr 2026
- InvestorsHHS
& 8 more
Associated legal entities of Endovascular Engineering
Endovascular Engineering operates through Ing Vysya Bank Limited, a listed company (amalgamated). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ing Vysya Bank Limited Listed CIN L85110KA1930PLC000124 | Amalgamated | 29 Mar 1930 | Bangalore, Karnataka | ₹2,262 Cr | – | 11 | View details |
Products & Services of Endovascular Engineering
Endovascular Engineering offers a comprehensive portfolio of products and services, including Hēlo Thrombectomy System.
Device for breaking down and removing blood clots via agitation and aspiration.
Funding Insights of Endovascular Engineering
Endovascular Engineering has successfully raised a total of $122M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in April 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $122M
- Total Rounds 4
- Last Round Series C — $80M
- First Round $298,197
(Sep 2021)
- Investors Count 9
All 4 funding rounds of Endovascular Engineering with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $80M | Series C | – | Gilde Healthcare, Norwest | |
| Feb 2025 | $42M | Series B | – | 415 CAPITAL, S3 Ventures | |
| Apr 2022 | – | Seed | – | Cordis, Sante | – |
| Sep 2021 | $298,197 | Grant | – | – |
9 investors in total: 9 institutional.
Investors in Endovascular Engineering
Endovascular Engineering has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Cordis and 415 Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in medical technology innovations. | – | 415capital.com | Munich, Germany | |
- | – | panakes.it | - | |
Venture capital investments are provided to Texas-based startups. | 2005 | s3vc.com | Austin, United States | |
A family investment firm based in Singapore, diversified across sectors. | – | mnlhealthcare.com | Singapore, Singapore | |
Santé is engaged in healthcare and technology investment management. | 2017 | sante.com | Minneapolis, United States | |
- | – | gildehealthcare.com | - | |
Cardiovascular and endovascular devices are developed and marketed by Cordis. | 1957 | cordis.com | Fremont, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
- | – | norwest.com | - |
Investor details for Endovascular Engineering
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Ing Vysya Bank Limited (Endovascular Engineering)
Ing Vysya Bank Limited is the primary company behind Endovascular Engineering. The board of Ing Vysya Bank Limited currently have 11 directors; the longest-serving is Maddali Venkata Satya Apparao, appointed in 2007. 15 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Maddali Venkata Satya Apparao DIN 00484877 | Company Secretary | 27 Jul 2007 | 19 yrs 2 mo | Ing Vysya Bank Limited |
| Santosh Desai DIN 01237902 | Director | 29 Apr 2008 | 18 yrs 5 mo | Ing Vysya Bank Limited |
| Meleveetil Damodaran DIN 02106990 | Director | 21 Jul 2008 | 18 yrs 2 mo | Ing Vysya Bank Limited |
| Vaughn Nigel Richtor DIN 00698356 | Director | 01 Jun 2009 | 17 yrs 4 mo | Ing Vysya Bank Limited |
| Vikram Talwar DIN 00416236 | Director | 20 Dec 2010 | 15 yrs 10 mo | Ing Vysya Bank Limited |
| Mark Edwin Newman DIN 03518417 | Director | 20 Apr 2011 | 15 yrs 6 mo | Ing Vysya Bank Limited |
| Jayant Mehrotra DIN 07681406 | CFO | 29 Apr 2014 | 12 yrs 5 mo | Ing Vysya Bank Limited |
| Alka Marezban Bharucha DIN 00114067 | Additional Director | 25 Jun 2014 | 12 yrs 3 mo | Ing Vysya Bank Limited |
| Adrianus Johannes Antonius Kas DIN 06853983 | Additional Director | 25 Jun 2014 | 12 yrs 3 mo | Ing Vysya Bank Limited |
| Kewal Kundanlal Handa DIN 00056826 | Additional Director | 12 Aug 2014 | 12 yrs 2 mo | Ing Vysya Bank Limited |
| David Han Lee Yong DIN 07015440 | Additional Director | 10 Nov 2014 | 11 yrs 11 mo | Ing Vysya Bank Limited |
People of Endovascular Engineering
7 people are tracked at Endovascular Engineering (3 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Bryan Leasure | Director of Clinical OPs | Leadership |
Margaret MacHado | Director Of Clinical Development And Training | Leadership |
Patricia Chu | Director Clinical Affairs | Leadership |
James Rose | Clinical Specialist | Team |
Hillary Huszar | Senior Research Development Manager | Team |
Vivi Lam | Quality Engineering Manager | Team |
Nathan Chan | Research And Development Engineer | Team |
Complete people profiles for Endovascular Engineering
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Endovascular Engineering
Figures of Ing Vysya Bank Limited, the primary company behind Endovascular Engineering, for FY 2024. Revenue was ₹2,262 Cr (0% year on year). Revenue has grown at a compounded annual rate of +7% over three years and +4% over five years.
- ₹2,262 CrRevenue · FY 2024 · 0% YoY
- ₹192 CrPaid-up capital
- +7%Revenue CAGR, 3 years
- +4%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Ing Vysya Bank Limited are on its company page.
Detailed financial statements for Endovascular Engineering
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Endovascular Engineering
3 dated milestones of Endovascular Engineering across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Endovascular Engineering is founded.
- Funding First funding round of $298K.
- Funding Latest funding round, Series C, of $80.0M.
Competitors of Endovascular Engineering
Endovascular Engineering has 6 listed competitors in our database, 3 of them funded. They include Inari Medical, Akura Medical, Magneto Thrombectomy, EmerStat and Retriever Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inarimedical.com | 2011 | Irvine, United States | $51.89M | 696 | Catheter-based thrombectomy devices for vascular emboli removal are developed. | |
| akuramed.com | 2021 | Campbell, United States | $60M | – | Catheter-based thrombectomy devices for thrombus removal are developed. | |
| magts.com | 2016 | Or Yehuda, Israel | – | – | Thrombectomy solutions are developed for blood clot removal in arteries. | |
| emerstat.com | 2022 | Singapore | – | – | Creates innovative hemostatic devices for efficient trauma care and surgical applications. | |
| rtvmed.com | 2020 | Las Vegas, United States | – | – | Provides medical devices for vascular care and clot removal treatments. | |
| nexgenmedsystem.com | 2002 | Reno, United States | $1.02M | – | Develops thrombectomy devices for the effective removal of blood clots. |
Detailed competitors of Endovascular Engineering
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Endovascular Engineering
The website of Endovascular Engineering (endovascularengineering.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 319.7% vs previous month
Top companies in Hematology
10 companies that operate in the same segment as Endovascular Engineering (Hematology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small activating RNA therapeutics are developed to restore gene function. | 2008 | London, England, United Kingdom | USD 460.41 M | USD 23.07 M | 37 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | – | 384 | |
Developer of therapeutics for the treatment of hematologic diseases | 2017 | Cambridge, Massachusetts, United States | USD 140 M | – | 84 | |
Gene therapy platform is developed for chronic disease treatments. | 2015 | Stevenage, Hertfordshire, United Kingdom | USD 273.69 M | USD 435.87 K | 152 | |
Novel anticoagulants for thrombosis treatment are developed. | 2019 | Cambridge, Massachusetts, United States | USD 250 M | – | 13 | |
Developer of therapies for treating hemochromatosis & beta thalassemia | 1989 | San Diego, California, United States | – | USD 75.72 M | 71 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Hematology products and solutions are provided for medical applications. | 1971 | Braintree, Massachusetts, United States | – | USD 1.33 B | 3,020 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Endovascular Engineering
Complete news archive for Endovascular Engineering
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Endovascular Engineering
Endovascular Engineering was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Endovascular Engineering is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Endovascular Engineering is a funded company, having raised a total of $122M across 4 funding rounds to date. The company's 1st funding round was a Grant of $298.2K, raised on Sep 2021.
The primary company behind Endovascular Engineering, Ing Vysya Bank Limited, reported revenue of ₹2,262 Cr for FY 2024, down 0% year on year.
Endovascular Engineering was established in 2019 in Menlo Park, United States. Services in engineering are offered to companies involved in medical device manufacturing. Focus is placed on supporting product development and production processes within the medical technology sector. Operations are conducted from the United States, with resources accessible via the domain endovascularengineering.com. Expertise is directed toward endovascular applications in device engineering.
Endovascular Engineering's top competitors include Inari Medical, Akura Medical and Magneto Thrombectomy.
Endovascular Engineering offers HÄ“lo Thrombectomy System.
Endovascular Engineering has 9 investors. Key investors include HHS, Cordis, 415 Capital, Panakes Partners, and S3 Ventures.
Endovascular Engineering operates through Ing Vysya Bank Limited.
The legal entities of Endovascular Engineering currently have 11 directors, including Mark Edwin Newman, Vikram Talwar, Vaughn Nigel Richtor and others.